| 10.79 -0.2 (-1.82%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.6 | 1-year : | 15.89 |
| Resists | First : | 11.64 | Second : | 13.6 |
| Pivot price | 11.13  |
|||
| Supports | First : | 10.16 | Second : | 9.23 |
| MAs | MA(5) : | 11.18 |
MA(20) : | 10.95 |
| MA(100) : | 10.09 |
MA(250) : | 8.34 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 48.2 |
D(3) : | 66.5 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 12.4 | Low : | 3.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMTX ] has closed above bottom band by 9.6%. Bollinger Bands are 40.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.23 - 11.32 | 11.32 - 11.39 |
| Low: | 10.38 - 10.48 | 10.48 - 10.54 |
| Close: | 10.66 - 10.81 | 10.81 - 10.92 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Tue, 28 Apr 2026
TD Cowen initiates Immatics stock coverage with buy rating - Investing.com
Tue, 28 Apr 2026
TD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendation - MSN
Thu, 23 Apr 2026
IMTX: Jefferies Analyst Biren Amin Rates Immatics with a "Buy" and Sets Price Target at $18.00 | IMTX Stock News - GuruFocus
Tue, 21 Apr 2026
Immatics (NASDAQ: IMTX) lines up four oral cancer therapy talks for ASCO 2026 - Stock Titan
Sun, 19 Apr 2026
Immatics (IMTX) Is Up 7.1% After Pediatric PRAME TCR Remission Case And AACR Spotlight - Has The Bull Case Changed? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 134 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 17.9 (%) |
| Held by Institutions | 76.4 (%) |
| Shares Short | 5,170 (K) |
| Shares Short P.Month | 5,160 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | 0 % |
| Operating Margin | -196.8 % |
| Return on Assets (ttm) | -18.1 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | -65 % |
| Gross Profit (p.s.) | -1.02 |
| Sales Per Share | 0.35 |
| EBITDA (p.s.) | -1.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -177 (M) |
| Levered Free Cash Flow | -128 (M) |
| PE Ratio | -5.68 |
| PEG Ratio | 0 |
| Price to Book value | 2.53 |
| Price to Sales | 29.97 |
| Price to Cash Flow | -8.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|